Author

Jinhyung Ahn

Observed name: JinHyung Albert Ahn

Institution: ABL Bio (South Korea)

Observed institutions: Hospital of the University of Pennsylvania, ABL Bio (South Korea)

ORCID: 0009-0009-4352-406X

Observed ORCID: 0009-0009-4352-406X

OpenAlex ID: A5134088706

Adverse Functional Effects of Chemotherapy on Whole-Brain Metabolism: A PET/CT Quantitative Analysis of FDG Metabolic Pattern of the “Chemo-Brain”

2013 · Jordan Sorokin, Babak Saboury, et al. · Clinical Nuclear Medicine · 33

ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al. · Molecular Cancer Therapeutics · 1

Data from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure 3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Table S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Table S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure 5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Table S4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure 2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure 4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S16 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S14 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure 1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure 6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S15 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S12 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Table S1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S13 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S8 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Figure S10 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window

2026 · Bora Lee, Hyeon Ji Park, et al.

Works count: 32

Citation count: 34

H-index: 1

I10-index: 1